Loading...
•
Sep 30, 2023
Alector Q3 2023 Earnings Report
Alector reported third quarter 2023 financial results and provided business update.
Key Takeaways
Alector reported a net loss of $44.5 million, or $0.53 per share, for the quarter ended September 30, 2023. As of September 30, 2023, Alector’s cash, cash equivalents and investments totaled $588.9 million, which is expected to fund operations through 2025.
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants
Enrollment completed in the INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’s disease in Q3 2023, data readout expected in Q4 2024
Company to host two virtual research and development events in December highlighting TREM2 and progranulin programs
$588.9 million in cash, cash equivalents and investments provide runway through 2025
Revenue by Segment
Forward Guidance
Management is reiterating its guidance for the year ending 2023. The company continues to anticipate collaboration revenue to be between $90 and $100 million, total research and development to be between $210 million and $220 million and total general and administrative expenses to be between $60 million and $65 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...